SERD

News

FDA's ODAC delivers one loss, one win for AstraZeneca

The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.

News

Roche's oral SERD flunks phase 3 breast cancer test

Roche's recent run of positive study results with breast cancer candidate giredestrant has come to an end with the failure of the persevERA trial.

News

Roche delivers its data reveal for adjuvant giredestrant

Roche reveals the data that has it excited about giredestrant in early-stage breast cancer, but how might it be positioned versus CDK4/6 inhibitors?

News

Roche extols 'unprecedented' result with breast cancer drug

Roche's oral SERD giredestrant has achieved what the company says is a stellar result as adjuvant treatment for early breast cancer.

News

Lilly brings second oral SERD to market for breast cancer

Lilly's Inluriyo is the second oral SERD to reach the US market for ESR1-mutated breast cancer, setting up a market tussle with Menarini's Orserdu.

News

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.

FDA's ODAC delivers one loss, one win for AstraZeneca

Roche's oral SERD flunks phase 3 breast cancer test

Roche delivers its data reveal for adjuvant giredestrant

Roche extols 'unprecedented' result with breast cancer drug

Lilly brings second oral SERD to market for breast cancer

Roche's oral SERD comes good in 2nd-line breast cancer trial

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

SERD

Editor's Picks